>1,000
peer reviewed publications reference G-Rex®.
Our mission
ScaleReady, a joint venture between Wilson Wolf Manufacturing and Bio-Techne, is the technical and commercial organization advancing G-Rex®-based drug product development and manufacturing. Our G-Rex® Optimization Specialists help teams design, implement, optimize, execute, and scale G-Rex®-centric workflows from early research through preclinical development, clinical manufacturing, and commercial production of approved therapies.
Our team brings decades of collective experience and an unconventional perspective to each challenge—reframing problems to identify practical solutions.
Explore G-Rex® Devices Explore Core Technology
The value of simplicity
The result is a superior CGT technology and the simplest way to develop and manufacture quality cell and gene therapy drug products.
The gold standard in cell & gene therapy
G-Rex®’s rich history includes pioneering work at storied institutions such as Baylor College of Medicine’s Center for Cell and Gene Therapy, Seattle Children’s Research Institute, and the National Cancer Institute’s Surgery Branch.
The scientific pedigrees and broad influence of these early pioneers helped establish G-Rex® as the default choice for cell and gene therapy researchers, developers, and manufacturers worldwide.
Because G-Rex® is widely used across academia and industry, it is familiar to major regulatory agencies—including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Chinese National Medical Products Administration (NMPA)—through its repeated inclusion in IND and CTA filings and its use in manufacturing commercially approved therapies.
>1,000
peer reviewed publications reference G-Rex®.
~50%
of US-based clinical trial sponsors have chosen G-Rex®.
6
commercially approved T cell therapies are produced in G-Rex® – including AMTAGVI® (lifileucel) – the world’s first and only approved tumor infiltrating lymphocyte (TIL) therapy for the treatment of a solid tumor cancer.
R&D → GMP
Cell & gene therapy organizations deploy scientists and engineers across drug product research, development & manufacturing. Having a common platform, especially as the bedrock of cell culture, can remove translational friction, mitigate risk in technology transfers, and promote continuous improvement.
True CGT platform technologies are rare because they must provide consistency in the culture environment, scalability in culture volume, and versatility across device formats.
G-Rex® is the only technology that can practically serve as a foundational platform across all major functions including R&D, Process & Analytical Development, clinical manufacturing, and commercial production.
Linear scale up (from miniature G-Rex® devices to full-scale, clinical grade G-Rex® bioreactors) simplifies and expedites your translation to full scale manufacturing with the least amount of time and money.
Linear scale-down from G-Rex® bioreactors to small-scale G-Rex® well plates enables time- and cost-efficient design of experiments (DoE) that accelerate pharmaceutical development and support Quality by Design.
Qualified reduced-scale G-Rex® models have been sanctioned by the FDA and EMA as a surrogate for full-scale G-Rex® clinical and commercial production.
Unlike mechanized bioreactors, where scaling out requires the addition of many more expensive, complicated, and cumbersome instruments, scaling out with G-Rex® primarily adds parallel vessels and incubator capacity as needed. With deliberate use of lean production methods, such as sequencing & level loading, leading CAR-T and TIL manufacturers are demonstrating why G-Rex® is the world’s most robust and scalable commercial manufacturing platform.
Applications by Cell Type
G-Rex® devices are well documented in supporting clinical and commercial production of a variety of different CGT modalities in both autologous and allogeneic applications.
G-Rex® supports most major CAR-T unit operations, is compatible with viral and nonviral gene-modification methods, and is deployed across point-of-care, decentralized or distributed, and centralized production models. This breadth allows developers to use the platform within the manufacturing model their program requires.
Explore G-Rex® for CAR-T cell therapyG-Rex® meets the needs of today’s TCR-T developers. High-density production supports demanding dose requirements, including for therapies targeting solid tumors. High-throughput capacity and operational simplicity can reduce manufacturing burden, improve efficiency, and help expand patient access.
Explore G-Rex® for TCR-T cell therapyG-Rex®’s history is deeply intertwined with the rise of TIL therapy. Its position as a gold-standard, market-leading platform reflects its longstanding use by pioneers at the NCI Surgery Branch and MD Anderson. ScaleReady estimates that more than 90% of TIL clinical trials (to date) utilize G-Rex.
Explore G-Rex® for TIL therapyG-Rex® devices have supported R&D and GMP manufacturing of NK and CAR-NK cell therapies for more than a decade across public hospitals, academic institutions, and biotechnology companies. Available formats support culture scales from approximately 1 × 10⁶ to 1 × 10¹¹ cells while preserving the underlying platform and core process logic.
Explore G-Rex® for NK cell therapyA robust literature base documents G-Rex® use in γδ T-cell therapy R&D and GMP manufacturing across Vδ1, Vδ2, and polyclonal approaches. This breadth of evidence supports its position as a gold-standard platform for developing and manufacturing γδ T-cell therapies.
Explore G-Rex® for γδ-T cell therapySmall-scale GMP grade G-Rex® bioreactors, beginning at 5 cm², accommodate the low starting-cell numbers common in Treg development. Leading academic institutions and biotechnology companies choose G-Rex for its simplicity and its ability to scale as their processes mature.
Explore G-Rex® for Treg therapyVST manufacturing must accommodate different donors, viral targets, stimulation or selection methods, and product models. G-Rex® provides a proven, simple, and scalable foundation across donor-specific, multivirus, third-party banked, and engineered VST workflows from initial antigen-specific stimulation through clinical-scale expansion.
Explore G-Rex® for VST therapyG-Rex® supports HSPC workflows across multiple starting materials and downstream cell products. Published studies document its use with CD34+ cells from cord blood, mobilized peripheral blood, and bone marrow.
Additional G-Rex® applications include Cytokine Induced Killer (CIK) cells, Natural Killer T (NKT) cells, pancreatic islet cells, dendritic cells (DCs) and other emerging cell types. G-Rex®’s range of device sizes and formats gives unconventional programs a practical platform for exploring process feasibility, scale, and transition toward manufacturing.
New Product Development
The simple architecture of G-Rex® provides a practical foundation for adding new capabilities without reinventing the core bioreactor. The platform remains stable while its capabilities evolve helping cell and gene therapy developers balance innovation with risk management and product comparability.
Passive resonant sensors responsive to secondary metabolites in culture provide orthogonal characterization of viable cell density and allow real time insight into process kinetics through non-invasive, contactless measurement.
Explore SMART G-Rex®
Specialized end-of-arm tooling is being engineered to allow robotic systems to handle G-Rex® without redesigning the bioreactor, supporting the development of automated G-Rex® workflows and end-to-end manufacturing.
Explore G-Rex® for RoboticsA better business model
The $42 million initiative has awarded more than 300 grants to academic and commercial organizations. Recipients receive non-dilutive access to G-Rex® devices, reagents, technical expertise, and partner resources helping them implement or optimize G-Rex® based processes that are ready to scale.
G-Rex® Grant Tour
Supporting the Emily Whitehead Foundation
In 2026, ScaleReady along with the Emily Whitehead Foundation embarked on a worldwide G-Rex® Grant Tour to rally local CGT communities around a common cause, create spaces for collaboration, and build momentum for ex vivo cell & gene therapies.
Choose wisely.
Your platform decision is never final, but every clinical data point generates more and more inertia in that direction.
Start a conversation
Tell us about your therapy and where you are in development. We’ll connect you with the right resources to catalyze your effort – no obligations, no red-tape, no sales script.
Connect to a G-Rex® Optimization Specialist
